Glenmede Trust CO Na Catalyst Pharmaceuticals, Inc. Transaction History
Glenmede Trust CO Na
- $20.6 Billion
- Q3 2024
A detailed history of Glenmede Trust CO Na transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Glenmede Trust CO Na holds 102,032 shares of CPRX stock, worth $2.21 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
102,032
Previous 101,599
0.43%
Holding current value
$2.21 Million
Previous $1.57 Million
28.93%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$404 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$174 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$135 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$123 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$65.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.22B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...